WuXi STA Completes Acquisition of BMS Manufacturing Facility
State-of-the-art facility in Couvet, Switzerland enhances WuXi STA's drug product capacity in Europe.
August 4, 2021
by contractpharma
Aptamer and WuXi AppTec Form Research Partnership
Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, have entered a research collaboration to identify new Optimer-enabled therapeutics.
July 23, 2021
by contractpharma
Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer enabled therapeutics
Aptamer Group, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.
July 23, 2021
by firstwordpharma
WuXi AppTec Completes OXGENE Acquisition
WuXi AppTec has completed the acquisition of OXGENE, a UK-based contract research and development organization that designs and develops scalable gene therapy technologies.
March 3, 2021
by contractpharma
WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia
As an enabler of the biotech and medical device industry, WuXi AppTec shares the conviction that we must work collaboratively to solve industry-wide problems and bring transformational medicines to people living with rare diseases.
July 9, 2020
by prnasia
WuXi AppTec Appoints Advanced Therapies CEO
Dr. Chang will provide strategic, scientific and operational leadership to the company's global cell and gene therapy R&D and manufacturing services.
June 2, 2020
by contractpharma
WuXi AppTec Wuhan Site Resumes Operation
WuXi AppTec announced today that the company's Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines.
March 12, 2020
by prnasia
WuXi AppTec Wuhan Site Resumes Ops
The Wuhan facility provides discovery chemistry services and will ramp up operations in the coming days and weeks.
March 12, 2020
by contractpharma
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
WuXi AppTec Research Service Division and BioSolveIT launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds ...
October 12, 2019
by En-CPhI.CN
WuXi AppTec to expedite early drug discovery
Launches DNA Encoded Library (DEL) Service Package "DELight"
September 4, 2019
by biospectrumasia
WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies
WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies.
July 2, 2019
by prnasia
China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering
With this buy, financial details of which are not being shared, WuXi Clinical boosts its biometrics capabilities in the U.S. and Europe.
May 12, 2019
by fiercepharma